Contact Information: For More Information, Contact: James E. Fickenscher Chief Financial Officer Auxilium Pharmaceuticals, Inc. (484) 321-5900 Gregory Gin Lazar Partners, Ltd. (212) 867-1762
Auxilium Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
| Source: Auxilium Pharmaceuticals, Inc.
MALVERN, PA--(Marketwire - August 27, 2007) - Auxilium Pharmaceuticals, Inc. (NASDAQ : AUXL )
today announced that Mr. Armando Anido, Chief Executive Officer and
President, and Mr. Jim Fickenscher, Chief Financial Officer, will
participate in the 2007 Thomas Weisel Partners Healthcare Conference to be
held September 5 through September 7, 2007 at the Four Seasons Hotel in
Boston, MA. Mr. Anido is scheduled to present an overview of the Company
and its product pipeline at 8:35 AM Eastern Time on Thursday, September 6,
2007.
To listen to the audio web cast of the presentation during or after the
event, please visit: http://www.auxilium.com. The replay will be available
for 30 days after the event.
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company
with a focus on developing and marketing to urologists, endocrinologists,
orthopedists and select primary care physicians. Auxilium markets
Testim® 1%, a topical testosterone gel, for the treatment of hypogonadism
through its approximately 190-person sales and marketing team. Auxilium
has four projects in clinical development. XIAFLEX (clostridial
collagenase for injection), formerly referred to as AA4500, is in phase III
of development for the treatment of Dupuytren's contracture and is in phase
II of development for the treatment of Peyronie's disease and Frozen
Shoulder syndrome (Adhesive Capsulitis). Auxilium's transmucosal film
product candidate for the treatment of overactive bladder (AA4010) is in
phase I of development. The Company is currently seeking a partner to
further develop this product candidate. Auxilium has two pain products
using its transmucosal film delivery system in pre-clinical development.
Auxilium has rights to six additional pain products and products for
hormone replacement and urologic disease using its transmucosal film
delivery system. Auxilium also has options to all indications using
XIAFLEX for non-topical formulations. For additional information, visit
http://www.auxilium.com.
SAFE HARBOR STATEMENT
This release contains "forward-looking-statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including statements
regarding the Company's intention to present at the 2007 Thomas Weisel
Partners Healthcare Conference, and products in development for the
treatment of Dupuytren's contracture, Peyronie's disease, Frozen Shoulder
syndrome, pain, hormone replacement and urologic disease. All statements
other than statements of historical facts contained in this release,
including but not limited to, statements regarding future expectations,
plans and prospects for the Company, statements regarding forward-looking
financial information and other statements containing the words "believe,"
"may," "could," "will," "estimate," "continue," "anticipate," "intend,"
"should," "plan," "expect," and similar expressions, as they relate to the
Company, constitute forward-looking statements. Actual results may differ
materially from those reflected in these forward-looking statements due to
various factors, including general financial, economic, regulatory and
political conditions affecting the biotechnology and pharmaceutical
industries and those discussed in the Company's Annual Report on Form 10-K
for the year ended December 31, 2006 and in the Company's Annual Report on
Form 10-Q for the quarter ended June 30, 2007 under the heading "Risk
Factors," which is on file with the Securities and Exchange Commission (the
"SEC") and may be accessed electronically by means of the SEC's home page
on the Internet at http://www.sec.gov or by means of the Company's home
page on the Internet at http://www.auxilium.com under the heading "Investor
Relations -- SEC Filings." There may be additional risks that the Company
does not presently know or that the Company currently believes are
immaterial which could also cause actual results to differ from those
contained in the forward-looking statements. Given these risks and
uncertainties, any or all of these forward-looking statements may prove to
be incorrect. Therefore, you should not rely on any such factors or
forward-looking statements.
In addition, forward-looking statements provide the Company's expectations,
plans or forecasts of future events and views as of the date of this
release. The Company anticipates that subsequent events and developments
will cause the Company's assessments to change. However, while the Company
may elect to update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as representing the
Company's assessments as of any date subsequent to the date of this
release.